130 related articles for article (PubMed ID: 2189591)
1. Intrapleural etoposide for malignant effusion.
Holoye PY; Jeffries DG; Dhingra HM; Holmes FA; Raber M; Engineer MS; Newman RA
Cancer Chemother Pharmacol; 1990; 26(2):147-50. PubMed ID: 2189591
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion.
Montaldo PG; Figoli F; Zanette ML; Sorio R; Zucchetti M; Tirelli U; D'Incalci M
Oncology; 1990; 47(1):55-61. PubMed ID: 2300386
[TBL] [Abstract][Full Text] [Related]
3. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer.
Tohda Y; Iwanaga T; Takada M; Yana T; Kawahara M; Negoro S; Okishio K; Kudoh S; Fukuoka M; Furuse K
Chemotherapy; 1999; 45(3):197-204. PubMed ID: 10224342
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions.
Monjanel-Mouterde S; Frenay C; Catalin J; Boutin C; Durand A; Astoul P
Oncol Rep; 2000; 7(1):171-5. PubMed ID: 10601613
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion.
Lerza R; Vannozzi MO; Tolino G; Viale M; Bottino GB; Bogliolo G; Cerruti A; Castello G; Mencoboni M; Reggiardo G; Pannacciulli I; Esposito M
Ann Oncol; 1997 Apr; 8(4):385-91. PubMed ID: 9209670
[TBL] [Abstract][Full Text] [Related]
7. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
[TBL] [Abstract][Full Text] [Related]
9. [Studies on an appropriate intra thoracic administration of cisplatin and sodium thiosulfate in malignant pleural effusion].
Kitajima K; Fukuoka M; Kusunoki Y; Negoro S; Takada M; Matsui K; Sakai N; Ryu S; Takifuji N; Masuda N
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3253-9. PubMed ID: 3196043
[TBL] [Abstract][Full Text] [Related]
10. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
Rusch VW; Niedzwiecki D; Tao Y; Menendez-Botet C; Dnistrian A; Kelsen D; Saltz L; Markman M
J Clin Oncol; 1992 Jun; 10(6):1001-6. PubMed ID: 1588364
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of local administration of ACNU in the treatment of malignant pleural effusion].
Honma T; Yoneda S; Yoshida S; Komuro Y; Takayama S
Gan To Kagaku Ryoho; 1982 Feb; 9(2):316-22. PubMed ID: 6964036
[TBL] [Abstract][Full Text] [Related]
12. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis.
Lombardi G; Nicoletto MO; Gusella M; Fiduccia P; Dalla Palma M; Zuin A; Fiore D; Donach M; Zagonel V
Cancer Chemother Pharmacol; 2012 Mar; 69(3):781-7. PubMed ID: 22037881
[TBL] [Abstract][Full Text] [Related]
13. Intrapleurally administered streptokinase in the treatment of acute loculated nonpurulent parapneumonic effusions.
Henke CA; Leatherman JW
Am Rev Respir Dis; 1992 Mar; 145(3):680-4. PubMed ID: 1546851
[TBL] [Abstract][Full Text] [Related]
14. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
Lerza R; Esposito M; Vannozzi M; Bottino GB; Bogliolo G; Pannacciulli I
Cancer; 1994 Jan; 73(1):79-84. PubMed ID: 8275441
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion.
Astoul P; Bertault-Peres P; Durand A; Catalin J; Vignal F; Boutin C
Cancer; 1994 Jan; 73(2):308-13. PubMed ID: 8293393
[TBL] [Abstract][Full Text] [Related]
16. The pathogenesis of low pleural fluid glucose in acidotic malignant pleural effusions.
Limthongkul S
J Med Assoc Thai; 1989 Sep; 72(9):492-7. PubMed ID: 2809454
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of aquaporin-1 on the pleura of rats with a tuberculous pleural effusion.
Du H; Xie C; He Q; Deng X
Lung; 2007 Dec; 185(6):325-36. PubMed ID: 17876668
[TBL] [Abstract][Full Text] [Related]
18. Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion.
Chatzika K; Manika K; Kontou P; Pitsiou G; Papakosta D; Zarogoulidis K; Kioumis I
Antimicrob Agents Chemother; 2014; 58(3):1315-9. PubMed ID: 24323477
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural alteplase in a patient with complicated pleural effusion.
Walker CA; Shirk MB; Tschampel MM; Visconti JA
Ann Pharmacother; 2003 Mar; 37(3):376-9. PubMed ID: 12639166
[TBL] [Abstract][Full Text] [Related]
20. Alteration in the levels of pyrazinamide in pleural fluid following simultaneous administration of prednisoline in patients of tubercular pleural effusion.
Wagay AR; Singhal KC; Bhargava R
Indian J Physiol Pharmacol; 1990 Oct; 34(4):259-62. PubMed ID: 2100288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
